ArticleBMJ neurology open2024

Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial.

Samantha G Brew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.